DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Conventional Step-Up Versus Infliximab Monotherapy in Patients With Ulcerative Colitis (P05553 AM2)

Information source: Merck Sharp & Dohme Corp.
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Colitis, Ulcerative

Intervention: Infliximab (Biological); Prednisolone (Drug); 5-aminosalicylic acid (Drug); Azathioprine (Drug)

Phase: Phase 3

Status: Terminated

Sponsored by: Merck Sharp & Dohme Corp.

Summary

This study will be performed to compare the efficacy and safety of the classical "Step-Up" approach for treatment of moderate-to-severe active ulcerative colitis using oral prednisolone + oral 5-aminosalicylic acid (5-ASA) or oral prednisolone + oral azathioprine (AZA) with a more intensive and early "Top-Hold" approach with intravenous infliximab (5 mg/kg) administered at Weeks 0, 2, and 6 and 8 weeks thereafter.

Clinical Details

Official title: Conventional Step-Up Versus Infliximab Monotherapy in Patients With Active Moderate to Severe Ulcerative Colitis. A Randomized, Open Label, Prospective, Multicenter Study

Study design: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome: Number of Participants With Response at Week 4 and Steroid-Free Remission at Week 50

Secondary outcome: Number of Participants Achieving Treatment Response

Detailed description: Participants will be randomized to receive either intravenous (IV) infliximab monotherapy (Top-Hold approach) starting at a dose of 5 mg/kg at Weeks 0, 2, and 6 and thereafter every 8 weeks in Level 1, or classical Step-Up treatment starting with oral prednisolone (40 mg/day for at least 3 days and at most 2 weeks followed by 1 mg/kg/day for a minimum of 7 days and up to 2 weeks in the case the participant does not show an improvement in clinical symptoms under 40 mg/day treatment) + oral 5-aminosalicylic acid (5-ASA) at a dose of 2 g/day in Level 1. Participants receiving Step-Up treatment who have not achieved adequate response during the first 4 weeks of prednisolone treatment will directly enter Level 3 treatment after endoscopy is performed to confirm treatment eligibility. Furthermore, participants that have not achieved response at Week 4 will also directly enter Level 3 and be switched to treatment with IV infliximab. If a participant experiences a first flare after initial response, participants in the Step-Up group will start prednisolone treatment at the last effective dose (i. e., participants that previously responded to prednisolone 40 mg/day will receive a dose of 40 mg/day for at least 3 days and up to 2 weeks; participants that previously responded to prednisolone 1 mg/kg/day will receive a dose of 1 mg/kg/day for a minimum of 7 days and up to 2 weeks). If the last effective dose was 40 mg/day and the participant does not respond within 14 days, the dose will be adjusted to 1 mg/kg/day for a minimum of 7 days and up to 2 weeks. In case the participant does not respond to prednisolone (i. e., does not return to their individual baseline partial Mayo score obtained at study Week 4), the participant will enter Level 3 and receive treatment with IV infliximab. If a participant experiences a second flare after initial response at Week 4 (Level 1), the participant will enter treatment Level 2. In Level 2, participants will receive a prednisolone induction at the same effective dose as previously used in Level 1 + maintenance treatment with oral azathioprine (AZA) at a dose of 2. 0-2. 5 mg/kg/day. Participants that do not respond to this treatment at Level 2 or that develop a further flare after initial response at Level 2 will enter Level 3 and will receive treatment with IV infliximab following endoscopy to confirm treatment eligibility. If at any time during treatment, a participant becomes prednisolone dependent (i. e., flare during tapering phase of prednisolone), the participant will enter Level 3 treatment with IV infliximab. Participants in Level 1 of the Top-Hold treatment group (IV infliximab at Week 0, 2, and 6 and every 8 weeks thereafter) that have not achieved response at Week 4 will receive IV infliximab 5 mg/kg at reduced intervals of 4 weeks (Level 2) starting with the Week 10 infusion. Participants suffering a flare after initial response in Level 1 will be switched to to Level 2. Participants that do not respond to treatment at reduced intervals after 3 infusions (12 weeks), or that develop a further flare after initial response at Level 2, will be switched to treatment with oral prednisolone + AZA (Level 3) following colonoscopy to confirm eligibility. When a participant responds to treatment with IV infliximab in Level 2, they will return to treatment with IV infliximab every 8 weeks when response is achieved at 3 consecutive visits.

Eligibility

Minimum age: 18 Years. Maximum age: N/A. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Any race or ethnicity

- Must have a diagnosis of moderate-to-severe active ulcerative colitis (UC) with

inflammation present beyond the rectum and including more than 20 cm of the colon (Mayo score of 6 to 12 points, inclusive ≥ 2 in the endoscopy subscore)

- Must have responded inadequately to oral (with or without topical) 5-ASA treatment

(prerequisite oral: at a minimum 4 g/d for 7 days) and must be considered for the first course of systemic corticosteroids; Participants with a UC and a Mayo score of ≥ 9 are also eligible without prior 5-ASA treatment

- Must agree to use acceptable methods of contraception for at least 2 weeks prior to

starting any study treatment and to continue until at least 6 months after the last doses of study drugs

- Laboratory results must be within specified limits

- Must be negative for colorectal cancer or any associated lesions

- Must have a negative tuberculosis (TB) test

- Must have a chest x-ray within the 3 months with no clinically significant

abnormality, or evidence of current active TB or latent TB

- Must have a negative stool culture

Exclusion Criteria:

- Pregnant, nursing, or planning pregnancy

- Had received previous treatment for UC with the corticosteroids, infliximab,

azathioprine/ 6-mercaptopurine (6-MP), cyclosporine, tacrolimus, methotrexate, sirolimus, mycophenolate, any tumor necrosis factor-alpha (TNF-α) inhibitor or receptor constructs that bind to ΤΝF-α (e. g., etanercept or adalimumab) and any other biologic agents

- Frequent (chronic) use of non-steroidal anti-inflammatory drugs (NSAIDs)

- Use of laxatives or any murine recombinant product

- Had surgery for active gastrointestinal bleeding, peritonitis, intestinal

obstruction, or intra-abdominal or pancreatic abscess requiring surgical drainage in previous 2 months

- History of colonic obstruction within the previous 6 months

- History of mucosal dysplasia, fistula or colonic resection, adenomatous polyps or

stoma, severe, fixed symptomatic stenosis of the large or small intestine

- Had serious infection with previous 2 months, including human immunodeficiency virus

(HIV) and hepatitis

- Had organ transplant (with the exception of a corneal transplant)

- Any malignancy within 5 years, including lymphoma

- History of demyelinating disease such as multiple sclerosis or optic neuritis

- Presence or history of congestive heart failure

- Requires chronic and frequent use of antimotility agents for control of diarrhea

- Requires total parenteral nutrition

- Had participated in any other clinical trial within 30 days or intention to

participate in another clinical trial during participation in this study

Locations and Contacts

Additional Information

Starting date: November 2009
Last updated: October 30, 2014

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017